Automated, Compact, Random Access Chemistry Analyzer Featured at AACC
|
By LabMedica International staff writers Posted on 18 Jul 2012 |

Image: Indiko chemical analyzer (Photo courtesy of Thermo Scientific).
AACC 2012: An automated, compact, random access chemistry analyzer is a cost-effective system designed for clinical chemistry and specialty testing.
Called Indiko, the Thermo Scientific (Waltham, MA, USA) chemical analyzer is being showcased at the 2012 annual conference of the American Association for Clinical Chemistry (AACC) Expo held at the Los Angeles Convention Center from July 15-19, 2012.
The benchtop analyzer is designed for routine clinical chemistry testing in small laboratory settings and specialty testing such as specific proteins, drug of abuse testing, and therapeutic drug monitoring including immunosuppressant drug monitoring (ISD).
A mix of bar-coded primary tubes and sample cups increase the flexibility of any operation. Patient oriented testing produces results quickly thus improving the quality of patient care.
With a small footprint, the Indiko analyzer fits ideally in a laboratory with space limitations. The graphical design of the user interface is supported by a touch screen.
Indiko includes several automated features, such as advanced dilution management and real-time monitoring of reagent usage, which help to manage a daily workload fluently. Samples, reagents, and consumables can continuously be loaded without interrupting the testing process, and different sample types can be analyzed at the same time.
A real-time QC program with multiple Westgard Rules assures the reliable performance. Application data as well as calibrator and control values are loadable from a file or from a two-dimensional barcode by the barcode scanner. The test flow definition allows for up to four reagent additions in each test, offering automation even for the most complex methods. The special cuvette design supports low reagent volumes thus reducing operating costs, especially important when working with specialty tests. Each cuvette is used only once to ensure accurate and precise results.
Related Links:
Thermofisher Scientific
Called Indiko, the Thermo Scientific (Waltham, MA, USA) chemical analyzer is being showcased at the 2012 annual conference of the American Association for Clinical Chemistry (AACC) Expo held at the Los Angeles Convention Center from July 15-19, 2012.
The benchtop analyzer is designed for routine clinical chemistry testing in small laboratory settings and specialty testing such as specific proteins, drug of abuse testing, and therapeutic drug monitoring including immunosuppressant drug monitoring (ISD).
A mix of bar-coded primary tubes and sample cups increase the flexibility of any operation. Patient oriented testing produces results quickly thus improving the quality of patient care.
With a small footprint, the Indiko analyzer fits ideally in a laboratory with space limitations. The graphical design of the user interface is supported by a touch screen.
Indiko includes several automated features, such as advanced dilution management and real-time monitoring of reagent usage, which help to manage a daily workload fluently. Samples, reagents, and consumables can continuously be loaded without interrupting the testing process, and different sample types can be analyzed at the same time.
A real-time QC program with multiple Westgard Rules assures the reliable performance. Application data as well as calibrator and control values are loadable from a file or from a two-dimensional barcode by the barcode scanner. The test flow definition allows for up to four reagent additions in each test, offering automation even for the most complex methods. The special cuvette design supports low reagent volumes thus reducing operating costs, especially important when working with specialty tests. Each cuvette is used only once to ensure accurate and precise results.
Related Links:
Thermofisher Scientific
Latest Clinical Chem. News
- Saliva-Based Test Detects Biochemical Signs of Sleep Loss
- Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
- Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
- Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation
- Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
- New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
- Blood-Based Biomarkers Show Promise for Psychosis Risk Prediction
- International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
- Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
- Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
- FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
- CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
- Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
Head and neck squamous cell carcinoma affects hundreds of thousands of people worldwide each year, yet response rates to immunotherapy remain low. Clinicians lack reliable, minimally invasive tools to... Read more
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








